CeriBell (NASDAQ:CBLL) Announces Earnings Results, Beats Estimates By $0.06 EPS

CeriBell (NASDAQ:CBLL) announced its earnings results on Tuesday. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06, Zacks reports. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. CeriBell updated its FY 2025 guidance to EPS.

CeriBell Stock Performance

CBLL traded down $0.42 during midday trading on Tuesday, reaching $10.92. The company had a trading volume of 347,488 shares, compared to its average volume of 286,289. The company has a debt-to-equity ratio of 0.11, a quick ratio of 12.91 and a current ratio of 13.31. The stock has a market cap of $400.33 million and a PE ratio of -3.65. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75. The business has a 50-day moving average price of $12.08 and a two-hundred day moving average price of $14.65.

Insider Activity at CeriBell

In related news, CTO Raymond Woo sold 11,112 shares of the company’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $12.54, for a total transaction of $139,344.48. Following the sale, the chief technology officer directly owned 167,704 shares in the company, valued at approximately $2,103,008.16. This represents a 6.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 20.10% of the company’s stock.

Institutional Trading of CeriBell

Institutional investors and hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its position in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of CeriBell by 148.6% during the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after buying an additional 5,200 shares in the last quarter. Invesco Ltd. purchased a new stake in shares of CeriBell during the 2nd quarter valued at $197,000. Quantbot Technologies LP raised its position in shares of CeriBell by 70.3% during the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after buying an additional 6,401 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of CeriBell by 197.9% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,651 shares of the company’s stock valued at $406,000 after buying an additional 14,382 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CBLL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. Raymond James Financial began coverage on shares of CeriBell in a research note on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, CeriBell has an average rating of “Moderate Buy” and a consensus target price of $30.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.